Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jan 18;17(1):e256524.
doi: 10.1136/bcr-2023-256524.

Eculizumab in severe Shiga toxin-mediated haemolytic uraemic syndrome

Mitchell Carroll  1 , Louise Blake  2 , Susheel Sharma  3
Affiliations
Case Reports

Eculizumab in severe Shiga toxin-mediated haemolytic uraemic syndrome

Mitchell Carroll et al. BMJ Case Rep. .

Abstract

Shiga toxin (Stx)-producing Escherichia coli-mediated haemolytic uraemic syndrome is a primary thrombotic microangiopathy, typified by the development of microangiopathic haemolytic anaemia, thrombocytopaenia and acute renal failure. It is a leading cause of acute renal failure in paediatrics, with a second peak in prevalence in adults over the age of 60. Presentations of Stx-producing E. coli-mediated haemolytic uraemic syndrome in young adults are rare. We present the case of a previously well female in her early 30s presenting with Stx-producing E. coli-mediated haemolytic uraemic syndrome with severe renal and neurological manifestations. Eculizumab was administered due to the severity of presentation and disease trajectory refractory to initial supportive therapy. A significant clinical and biochemical improvement was observed following eculizumab.

Keywords: Acute renal failure; Epilepsy and seizures; Haematology (incl blood transfusion); Hepatitis and other GI infections; Renal system.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Joseph A, Cointe A, Mariani Kurkdjian P, et al. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins (Basel) 2020;12:67. 10.3390/toxins12020067 - DOI - PMC - PubMed
    1. Trachtman H, Austin C, Lewinski M, et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012;8:658–69. 10.1038/nrneph.2012.196 - DOI - PubMed
    1. Majowicz SE, Scallan E, Jones-Bitton A, et al. Global incidence of human Shiga toxin–producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis 2014;11:447–55. 10.1089/fpd.2013.1704 - DOI - PMC - PubMed
    1. Travert B, Rafat C, Mariani P, et al. Shiga toxin-associated hemolytic uremic syndrome: specificities of adult patients and implications for critical care management. Toxins (Basel) 2021;13:306. 10.3390/toxins13050306 - DOI - PMC - PubMed
    1. Braune SA, Wichmann D, von Heinz MC, et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 2013;41:1702–10. 10.1097/CCM.0b013e31828a24a8 - DOI - PubMed

Publication types

MeSH terms